

Treatments for Tardive Dyskinesia: Effectiveness and Value

Tuesday, December 5, 2017 10:00 AM – 4:00 PM Lunch available at 12:15pm

Grand Ballroom, Boston Marriott Newton 2345 Commonwealth Ave Newton, MA 02466

Time	Activity	
9:30 am - 10:00 am	Registration	
10:00 am - 10:15 am	Meeting Convened and Opening Remarks:	
	Steven Pearson, MD, MSc, President, ICER	
10:15 am - 10:25 am	The Patient Experience with Tardive Dyskinesia: Results from a Patient Survey	
	Presentation by Allen Doederlein, President, Depression and Bipolar Support Alliance	
10:25 am - 11:25 am	5 am Presentation of the Evidence	
	Steven J. Atlas, MD, MPH, Director, Primary Care Research and Quality	
	Improvement Network, Massachusetts General Hospital	
	Surrey M Walton, PhD, University of Illinois at Chicago College of Pharmacy	
	Daniel R. Touchette, PharmD, MA, FCCP, University of Illinois at Chicago	
	College of Pharmacy	
11:25 am - 11:45 am	Manufacturer Comments and Discussion	
11:45 am - 12:15 pm	m - 12:15 pm Public Comments and Discussion	
	Members of the public pre-registered to deliver oral remarks	
12:15 pm - 1:00 pm	Break for Lunch	
1:00 pm - 2:00 pm	New England CEPAC Deliberation and Vote of Clinical Effectiveness and Value	
	ICER staff and clinical experts are available for questions from the Council	
	during deliberation	
2:00 pm - 3:30 pm	Policy Roundtable	
3:30 pm - 4:00 pm	Reflections from New England CEPAC Panel	
4:00 pm	Meeting Adjourned	

Policy Roundtable:

Victor Abler, DO. Senior Global Medical Director for Neurodegenerative Diseases, Teva Pharmaceuticals
Teri Brister, PhD. Director Knowledge Integration Information, National Alliance on Mental Illness
Oliver Freudenreich, MD. Co-Director, Mass General Hospital Schizophrenia Clinical Research Program
Patrick Hendry, Vice President of Peer Advocacy Support and Services, Mental Health America
Barbara Henry, RPh. Lead Clinical Pharmacy Specialist, Harvard Pilgrim
Paul Jeffrey, PharmD. Director of Pharmacy, MassHealth
Daniel Tarsy, MD. Professor of Neurology; Parkinson's Disease and Movement Disorders Center, Beth Israel, Harvard Medical School
Chuck Yonan, PharmD. Senior Director HEOR, Medical Affairs, Neurocrine Bioscience

Participating Members of New England CEPAC			
Robert H. Aseltine, Jr., PhD	Dora Anne Mills, MD, MPH Vice President for Clinical Affairs University of New		
Professor in the Division of Behavioral Sciences and Community Health; Deputy Director of the Center for Public Health and Health	England		
Policy;			
Director of the Institute for Public Health Research University of Connecticut			
Stacey Brown, PhD	Stephanie Nichols, Pharm.D., BCPS, BCPP		
Director for Community-based Education,	Associate Professor of Pharmacy Practice, Husson		
Asst. Professor of Community Medicine and Healthcare	University; Psychiatric Pharmacist, Maine Medical Center		
University of Connecticut School of Medicine			
Gregory Curfman, MD	Brian P. O'Sullivan, MD		
Editor in Chief	Professor of Pediatrics		
Harvard Health Publications	Geisel School of Medicine, Dartmouth College		
Austin Frakt, PhD	Julia Prentice, PhD		
Health Economist; Department of Veterans Affairs	Director, Health Care Financing and Economics		
Boston University; Harvard University	VA Boston Healthcare System		
Claudia Gruss, MD, FACP, FACG, CNSC	Jeanne Ryer, MSc, EdD		
Gastroenterologist and Internist, Arbor Medical Group, LLC	Director, NH Citizens Health Initiative		
Claudio W. Gualtieri, JD	Keith Stahl, MD, FACP		
Associate State Director of Advocacy	Medical Director and Primary Care Internist; Family		
AARP's Connecticut State Office	Health and Wellness Center at Bedford, NH; Adjunct		
	Professor, Dartmouth Medical School		
Stephen Kogut, PhD, MBA RPh	Rev. Albert Whitaker, MA		
Professor of Pharmacy Practice	Director of Community Partnerships, New England		
University of Rhode Island College of Pharmacy	American Diabetes Association		
Kimberly Lenz, PharmD (ex officio)	Edward Westrick, PhD, MD		
Clinical Pharmacy Manager, MassHealth	Primary Care Physician, Assistant Medical Director,		
	Comprehensive Community Action Program		

*No relevant conflicts of interest to disclose, defined as more than \$25,000 in healthcare company stock or more than \$50,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers.

Institute for Clinical and Economic Review (ICER) Staff and Consultants

Foluso Agboola, MBBS, MPH, Research Scientist, ICER Steven J. Atlas, MD, MPH, Director, Primary Care Research and Quality Improvement Network, Massachusetts General Hospital Rick Chapman, PhD, MS, Dir. of Health Economics, ICER Alexandra Ellis, MSc, AM, Senior Scientist, ICER Katherine Fazioli, BS, Research Assistant, ICER Varun Kumar, MBBS, MPH, MSc, Health Economist, ICER Erin Lawler, MA, Communications Manager, ICER Molly Morgan, BA, Program and Event Coordinator, ICER

Aqsa Mugal, BA, Research Assistant, ICER Dan Ollendorf, PhD, Chief Scientific Officer, ICER Ifeoma Otuonye, MPH, Research Associate, ICER Steve Pearson, PhD, President and CEO, ICER Celia Segel, MPP, Program Manager Daniel R. Touchette, PharmD, MA, FCCP, University of Illinois at Chicago College of Pharmacy Surrey M Walton, PhD, University of Illinois at Chicago College of Pharmacy David Whitrap, BA, BES, Vice President of Communications and Outreach